Literature DB >> 29200159

Posterior Reversible Encephalopathy Syndrome: Risk Factors and Impact on the Outcome in Children With Acute Lymphoblastic Leukemia Treated With Nordic Protocols.

Joanna S Banerjee1, Mats Heyman2, Maarit Palomäki3, Päivi Lähteenmäki4, Mikko Arola5, Pekka V Riikonen6, Merja I Möttönen7, Tuula Lönnqvist8, Mervi H Taskinen1, Arja H Harila-Saari2.   

Abstract

Posterior reversible encephalopathy syndrome (PRES) in children with acute lymphoblastic leukemia has been increasingly recognized as a clinicoradiological entity. Our aim was to describe the incidence of PRES in pediatric patients with ALL, identify its risk factors, and examine its prognostic importance. For this research, we conducted a systematic, retrospective review of the patient records in a population-based series of children with acute lymphoblastic leukemia (n=643) treated in Finland from 1992 to 2008. Of the patients with ALL, 4.5% (n=29) developed radiologically confirmed PRES, of which 28 cases occurred during induction. Hypertension (P=0.006; odds ratio [OR], 4.10, confidence interval [CI], 1.50-11.25), constipation (P=0.001; OR, 5.60; CI, 2.02-15.52), and >14 days of alkalinization (P=0.017; OR, 3.27; CI, 1.23-8.68) were significant independent risk factors for PRES. One-third of the patients developed epilepsy. Relapses occurred significantly more often in those patients with PRES (P=0.001), which was associated with worse overall survival (P=0.040; 5-year survival=75.9% [60.3%-91.4%] vs. 88.4% [85.8%-90.9%]). Using NOPHO-ALL 92/2000 protocols, PRES is a significant early complication of therapy in ALL, and was associated with a poorer prognosis and significant neurological morbidity.

Entities:  

Mesh:

Year:  2018        PMID: 29200159     DOI: 10.1097/MPH.0000000000001009

Source DB:  PubMed          Journal:  J Pediatr Hematol Oncol        ISSN: 1077-4114            Impact factor:   1.289


  4 in total

1.  Clinical features, predictors and outcome of posterior reversible encephalopathy syndrome (PRES) in children with hematolymphoid malignancies.

Authors:  Subramaniam Ramanathan; Vignesh Subramani; Seema Kembhavi; Maya Prasad; Nirmalya Roy Moulik; Chetan Dhamne; Gaurav Narula; Shripad Banavali
Journal:  Childs Nerv Syst       Date:  2022-05-25       Impact factor: 1.532

2.  Clinical Analysis of Childhood Acute Lymphoblastic Leukemia With Epilepsy Seizures.

Authors:  Rui Li; Ji-Hong Tang; Bing-Bing Zhang; Xiao-Yan Shi; Yuan-Yuan Dai; Rui Qu
Journal:  Front Neurol       Date:  2022-05-10       Impact factor: 4.086

Review 3.  Neurotoxic Effects of Childhood Cancer Therapy and Its Potential Neurocognitive Impact.

Authors:  Nicholas S Phillips; Elizabeth S Duke; Hannah-Lise T Schofield; Nicole J Ullrich
Journal:  J Clin Oncol       Date:  2021-04-22       Impact factor: 50.717

4.  Management and Clinical Outcome of Posterior Reversible Encephalopathy Syndrome in Pediatric Oncologic/Hematologic Diseases: A PRES Subgroup Analysis With a Large Sample Size.

Authors:  Marady Hun; Min Xie; Zhou She; Amin S Abdirahman; Cuifang Li; Feifeng Wu; Senlin Luo; Phanna Han; Rithea Phorn; Pan Wu; Haiyan Luo; Keke Chen; Jidong Tian; Wuqing Wan; Chuan Wen
Journal:  Front Pediatr       Date:  2021-07-01       Impact factor: 3.418

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.